In CTEPH, antioxidant enzyme PRDX2 reduces inflammation

Robyn Kalda
Feb 2
1 min read

A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy patients. Using rats, the researchers determined that PRDX2 helped reduce inflammation, suggesting that it has a protective role and might have therapeutic use.

Read the Scientific Reports article

Recent Posts

Sotatercept and cardiopulmonary comorbidities

This study from one clinic examined how well sotatercept worked in real-world patients with pulmonary arterial hypertension (PAH) who also had other heart or lung conditions, such as coronary artery d

Start up: Supporting PAH patients beginning prostanoids

This study looked at a French support program designed to help people with pulmonary arterial hypertension (PAH) start and adjust their dose of selexipag. Nurses called patients three days after patie

Sotatercept vs. selexipag in severe PAH

Researchers used AI to indirectly compare data from three randomized controlled trials looking at sotatercept or selexipag in pulmonary arterial hypertension (PAH). Their findings suggest that sotater

Comments